Protocol Ledger

NCT05174169 · Phase II/III · RECRUITING

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Interventional Phase II/III clinical trial protocol NCT05174169 sponsored by NRG Oncology in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-07-08 Enrollment: 1,912 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05174169
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,912 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05174169
Protocol FieldVerified Registry Value
NCT IdentifierNCT05174169
Consolidated Lead SponsorNRG Oncology
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment1,912 participants (ESTIMATED)
Registered Start Date2022-07-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05174169
Hospital Research SiteLocationSite Profile
University of Alabama at Birmingham Cancer CenterBirmingham, ALOpen Hospital Dossier ->
Kingman Regional Medical CenterKingman, AZOpen Hospital Dossier ->
Cancer Center at Saint Joseph'sPhoenix, AZOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI